Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients

Clinical trial NCT03473574 · COMPLETED

Trial details

NCT number: NCT03473574
Sponsor: AIO-Studien-gGmbH
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Cholangiocarcinoma Gall Bladder Carcinoma Cholangiocarcinoma Non-resectable Gallbladder Carcinoma Non-Resectable

Start date: 2018-05-02
Primary completion: 2022-03-15
Enrollment: 128

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.